Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial-Reference-Cited by-同舟云学术

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Published:2020-12 Issue:12 Volume:21 Page:1630-1642
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kumar Shaji K,Harrison Simon J,Cavo Michele,de la Rubia Javier,Popat Rakesh,Gasparetto Cristina,Hungria Vania,Salwender Hans,Suzuki Kenshi,Kim Inho,Punnoose Elizabeth A,Hong Wan-Jen,Freise Kevin J,Yang Xiaoqing,Sood Anjla,Jalaluddin Muhammad,Ross Jeremy A,Ward James E,Maciag Paulo C,Moreau Philippe

Funder

AbbVie

Genentech

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Multiple myeloma;Kumar;Nat Rev Dis Primers,2017

2. Multiple myeloma: review of 869 cases;Kyle;Mayo Clin Proc,1975

3. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group;Laubach;Leukemia,2016

4. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study;Kumar;Leukemia,2017

5. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

Cited by 263 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11

2. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

3. Flow cytometric expression of Bcl-2, Mcl-1, and their ratios correlates with primary and secondary cytogenetic changes and their combinations in multiple myeloma;Annals of Hematology;2024-09-12

4. Navigating the clinical landscape: Update on the diagnostic and prognostic biomarkers in multiple myeloma;Molecular Biology Reports;2024-09-09

5. Monitoring Overall Survival in Pivotal Trials in Indolent Cancers;Statistics in Biopharmaceutical Research;2024-09-03